ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1072

Efficacy and Safety Assessment of a Rituximab Biosimilar in Patients with Granulomatosis with Polyangiitis (GPA)

Adil Vural1, Komal Mushtaq1, Chao Zhang1, Mahmoud Alwakeel1, Vickie Sayles1, Kristine Duly2, Carol Langford1 and Rula Hajj-Ali3, 1Cleveland Clinic, Cleveland, OH, 2Cleveland Clinic, Fairview Park, OH, 3Cleveland Clinic, Hunting Valley, OH

Meeting: ACR Convergence 2022

Keywords: ANCA, ANCA associated vasculitis, Biologicals, Granulomatosis with Polyangiitis (GPA), Vasculitis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Vasculitis – ANCA-Associated Poster II: Treatment Efficacy, Clinical Outcomes, Biomarkers

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: A biosimilar is a medication that is highly similar to a biologic agent that is already approved by a regulatory organization. Considering the share of health care expenditures attributable to biologic medicines, the use of a biosimilar presents a chance to reduce costs. Rituximab is an effective treatment option for maintaining remission in ANCA-associated vasculitis (AAV). Our goal was to compare the efficacy and safety of the rituximab biosimilar Ruxience® [Rituximab-pvvr (RTX-pvvr)], to that of its originator, Rituxan® [Rituximab (RTX)], in maintaining remission in patients with granulomatosis with polyangiitis (GPA).

Methods: This is a retrospective, single-center cohort study based on data obtained from electronic medical records. Eligible patients were adults with GPA, followed at the Vasculitis Center for at least two outpatient visits who were in remission (BVAS/WG≤ 1 and Prednisone dose≤ 10 mg/day) after receiving RTX for at least one year of maintenance therapy and then transitioned to an equivalent dose of RTX-pvvr for continuation of maintenance therapy in 2021. The primary endpoint was remission rate (BVAS/WG ≤ 1 and/or Prednisone dose ≤ 10 mg/day) at 6 months after transitioning to RTX-pvvr. Secondary endpoints were: 1- Infections requiring hospitalization; 2- Infusion reactions (classified based on National Cancer Institute Common Terminology Criteria for Adverse Events), and 3- Patient reported outcomes measurement (PROMIS) among RTX vs RTX-pvvr. McNemar test was performed for assessment of primary and secondary endpoints. Categorical Measures were summarized with frequency (%), and analyzed with Pearson’s Chi-square or Fisher’s exact test, where appropriate. Continuous measures were summarized with mean (SD) or median (25th, 75th quartile), and analyzed with two-sample t-tests, or Wilcoxon-Mann Whitney tests depending on the normality of the data.

Results: A total of 43 patients met the inclusion criteria. 58.1% were female, 97.7% white, with a mean age of 40.7 years (SD 13.7)(Table-1). The most commonly involved organ systems were ENT (79.1%), pulmonary (69.8%) and renal (55.8%). Of the 43 patients in remission who transitioned to RTX-pvvr, 42 (97.7%) remained in remission, while 1 (2.3%) had a non-severe disease relapse (BVAS/WG=2) and none had a severe disease relapse (p=1.0) (Table-2). Three out of 43 (6.98%) patients on RTX had infections requiring admission for intravenous antibiotics throughout the 6-month post-RTX infusion, whereas no infections were reported on RTX-pvvr (p=0.248). Infusion related reactions were reported in 2 (4.65%) and 3 (6.98%) out of 43 patients on RTX and RTX-pvvr (p=1.0), respectively. All infusion reactions recorded were grade 2 infusion reactions requiring infusion interruption briefly and symptomatic treatment. PROMIS data did not show any differences between the 2 cohorts (Figure-1).

Conclusion: Our results suggest that stable patients on maintenance RTX therapy remained in remission when switched to RTX-pvvr in the majority of patients with GPA. Infusion reactions, infection rates and PROMIS data were comparable among patients who received RTX-pvvr and RTX. Larger studies with larger number of patients are needed to validate our results.

Supporting image 1

Table 1. Baseline characteristics of study population.

Supporting image 2

Table 2. Assessment of endpoints by treatment.

Supporting image 3

Figure 1. PROMIS (Patient-Reported Outcomes Measurement Information System) scores within 1 year of maintenance therapy.


Disclosures: A. Vural, None; K. Mushtaq, None; C. Zhang, None; M. Alwakeel, None; V. Sayles, None; K. Duly, None; C. Langford, None; R. Hajj-Ali, uptodate.

To cite this abstract in AMA style:

Vural A, Mushtaq K, Zhang C, Alwakeel M, Sayles V, Duly K, Langford C, Hajj-Ali R. Efficacy and Safety Assessment of a Rituximab Biosimilar in Patients with Granulomatosis with Polyangiitis (GPA) [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/efficacy-and-safety-assessment-of-a-rituximab-biosimilar-in-patients-with-granulomatosis-with-polyangiitis-gpa/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-and-safety-assessment-of-a-rituximab-biosimilar-in-patients-with-granulomatosis-with-polyangiitis-gpa/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology